Estimating prognosis for survival after treatment of choroidal melanoma

Progress in Retinal and Eye Research

Volumn 30, Issue 5, 2011, Pages 285-295

  Damato, Bertil ^a   Eleuteri, Antonio ^a   Taktak, Azzam F G ^a   Coupland, Sarah E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chromosome aberrations; Histology; Mathematical modeling; Melanoma; Mortality; Prognostication; Uveal melanoma

Indexed keywords

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL INFILTRATION; CELL PROLIFERATION; CELL STRUCTURE; CHOROID MELANOMA; CHROMOSOME; CHROMOSOME 1P; CHROMOSOME 3; CHROMOSOME 6P; CHROMOSOME LOSS; CHROMSOME 8; CILIARY BODY; CLINICAL PRACTICE; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTON THERAPY; REVIEW; RISK FACTOR; TUMOR VOLUME; UVEA MELANOMA;

AGE FACTORS; CELL PROLIFERATION; CHOROID NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MELANOMA; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 79960196365     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2011.05.003     Document Type: Review

References (56)

1. Ah-Fat F.G., Damato B.E. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye 1998, 12:781-782.
2. Akgul H., Otterbach F., Bornfeld N., Jurklies B. Intraocular biopsy using special forceps: a new instrument and refined surgical technique. Br. J. Ophthalmol. 2011, 95:79-82.
3. Al Jamal R.T., Mäkitie T., Kivelä T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest. Ophthalmol. Vis. Sci. 2003, 44:2381-2389.
4. Al-Jamal R.T., Kivelä T. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr. Eye Res. 2006, 31:57-67.
5. All-Ericsson C., Girnita L., Seregard S., Bartolazzi A., Jager M.J., Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest. Ophthalmol. Vis. Sci. 2002, 43:1-8.
6. Angi M., Damato B., Kalirai H., Dodson A., Taktak A., Coupland S.E. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 2009.
7. Augsburger J.J., Correa Z.M., Shaikh A.H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 2009, 148:119-127.
8. Bauer J., Kilic E., Vaarwater J., Bastian B.C., Garbe C., de Klein A. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br. J. Cancer 2009, 101:813-815.
9. Cook S.A., Damato B., Marshall E., Salmon P. Reconciling the principle of patient autonomy with the practice of informed consent: decision-making about prognostication in uveal melanoma. Health Expect. 2010, 10-7625.
10. Cook S.A., Damato B., Marshall E., Salmon P. Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research. Eye 2008, 10.1038/eye.2008.54.
11. Coupland S.E., Campbell I., Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 2008, 115:1778-1785.
12. Damato B. Does ocular treatment of uveal melanoma influence survival?. Br. J. Cancer 2010, 103:285-290.
13. Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol. Opt. 2001, 21:268-271.
14. Damato B. Legacy of the collaborative ocular melanoma study. Arch. Ophthalmol. 2007, 125:966-968.
15. Damato B., Coupland S.E. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond.) 2009, 23:2152-2160.
16. Damato B., Duke C., Coupland S.E., Hiscott P., Smith P.A., Campbell I., Douglas A., Howard P. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 2007, 114:1925-1931.
17. Damato B., Eleuteri A., Fisher A.C., Coupland S.E., Taktak A.F. Artificial neural networks estimating survival probability after treatment of choroidal melanoma. Ophthalmology 2008, 115:1598-1607.
18. Damato B.E., Dopierala J.A., Coupland S.E. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin. Cancer Res. 2010, 16:6083-6092.
19. Desjardins L., Dorval T., Lévy C., Cojean I., Schlienger P., Salmon R.J., Validire P., Asselain B. Randomised study on adjuvant therapy by DTIC in choroidal melanoma. Ophtalmologie 1998, 12:168-173.
20. Dopierala J., Damato B.E., Lake S.L., Taktak A.F., Coupland S.E. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest. Ophthalmol. Vis. Sci 2010.
21. Eleuteri, A., Damato, B., Coupland, S.E., Taktak, A.F.G., in press. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. J. Biomed. Eng. Tech.
22. Ericsson C., Seregard S., Bartolazzi A., Levitskaya E., Ferrone S., Kiessling R., Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:2153-2156.
23. Finger P.T. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. Arch. Pathol. Lab. Med. 2009, 133:1197-1198.
24. Folberg R., Rummelt V., Parys-Van Ginderdeuren R., Hwang T., Woolson R.F., Pe'er J., Gruman L.M. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993, 100:1389-1398.
25. Hakulinen T.R., Dyba T.A. Recent developments in relative survival analysis. Outcome Prediction in Cancer 2007, 43-64. Elsevier, Amsterdam. A.F.G. Taktak, A.C. Fisher (Eds.).
26. Harbour J.W. Molecular prognostic testing and individualized patient care in uveal melanoma. Am. J. Ophthalmol. 2009, 148:823-829.
27. Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley L.A., Council M.L., Matatall K.A., Helms C., Bowcock A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
28. Harrell F.E.J. Parametric survival models. Regression Modeling Strategies 2001, 413-441. Springer.
29. Jager M.J., Ly L.V., El Filali M., Madigan M.C. Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes?. Prog. Retin. Eye Res. 2011, 30:129-146.
30. Jmor F., Kalirai H., Taktak A., Damato B., Coupland S.E. HSP-27 protein expression in uveal melanoma: correlation with predicted survival. Acta Ophthalmol. 2010, 10-3768.
31. Johansson C.C., Mougiakakos D., Trocme E., All-Ericsson C., Economou M.A., Larsson O., Seregard S., Kiessling R. Expression and prognostic significance of iNOS in uveal melanoma. Int. J. Cancer 2009, 126:2682-2689.
32. Kilic E., Naus N.C., van Gils W., Klaver C.C., van Til M.E., Verbiest M.M., Stijnen T., Mooy C.M., Paridaens D., Beverloo H.B., Luyten G.P., de Klein A. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 2005, 46:2253-2257.
33. Kim I.K., Lane A.M., Gragoudas E.S. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch. Ophthalmol. 2010, 128:871-875.
34. Kujala E., Mäkitie T., Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:4651-4659.
35. Lin A.Y., Maniotis A.J., Valyi-Nagy K., Majumdar D., Setty S., Kadkol S., Leach L., Pe'er J., Folberg R. Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch. Pathol. Lab. Med. 2005, 129:884-892.
36. Maat W., van der Slik A.R., Verhoeven D.H., Alizadeh B.Z., Ly L.V., Verduijn W., Luyten G.P., Mulder A., van Hall T., Koning F., Jager M.J., van Bergen J. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 2009, 50:2888-2895.
37. Mäkitie T., Carpen O., Vaheri A., Kivelä T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:2442-2449.
38. Mäkitie T., Kivelä T. Cardiac metastasis from uveal melanoma. Arch. Ophthalmol. 2001, 119:139-140.
39. Mäkitie T., Summanen P., Tarkkanen A., Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:1414-1421.
40. Mäkitie T., Summanen P., Tarkkanen A., Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J. Natl. Cancer Inst. 1999, 91:359-367.
41. McLean I.W., Zimmerman L.E., Evans R.M. Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am. J. Ophthalmol. 1978, 86:557-564.
42. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004, 64:7205-7209.
43. Onken M.D., Worley L.A., Tuscan M.D., Harbour J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J. Mol. Diagn. 2010, 12:461-468.
44. Parrella P., Sidransky D., Merbs S.L. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res. 1999, 59:3032-3037.
45. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jöckel K.H., Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996, 347:1222-1225.
46. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin. Oncol. 2010, 37:127-138.
47. Seddon J.M., Albert D.M., Lavin P.T., Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch. Ophthalmol. 1983, 101:1894-1899.
48. Seregard S., Spangberg B., Juul C., Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 1998, 105:485-491.
49. Shields C.L., Furuta M., Thangappan A., Nagori S., Mashayekhi A., Lally D.R., Kelly C.C., Rudich D.S., Nagori A.V., Wakade O.A., Mehta S., Forte L., Long A., Dellacava E.F., Kaplan B., Shields J.A. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol. 2009, 127:989-998.
50. Shields C.L., Ganguly A., Bianciotto C.G., Turaka K., Tavallali A., Shields J.A. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011, 118:396-401.
51. Trolet J., Hupe P., Huon I., Lebigot I., Decraene C., Delattre O., Sastre-Garau X., Saule S., Thiery J.P., Plancher C., Asselain B., Desjardins L., Mariani P., Piperno-Neumann S., Barillot E., Couturier J. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest. Ophthalmol. Vis. Sci. 2009, 50:2572-2580.
52. Virgili G., Gatta G., Ciccolallo L., Capocaccia R., Biggeri A., Crocetti E., Lutz J.M., Paci E. Survival in patients with uveal melanoma in Europe. Arch. Ophthalmol. 2008, 126:1413-1418.
53. Voelter V., Schalenbourg A., Pampallona S., Peters S., Halkic N., Denys A., Goitein G., Zografos L., Leyvraz S. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res. 2008, 18:220-224.
54. Whelchel J.C., Farah S.E., McLean I.W., Burnier M.N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 1993, 34:2603-2606.
55. White V.A., Chambers J.D., Courtright P.D., Chang W.Y., Horsman D.E. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998, 83:354-359.
56. Young T.A., Burgess B.L., Rao N.P., Gorin M.B., Straatsma B.R. High-density genome array is superior to fluorescence in-situ hybridization analysis of monosomy 3 in choroidal melanoma fine needle aspiration biopsy. Mol. Vis. 2007, 13:2328-2333.